Ignite Creation Date:
2025-12-24 @ 5:17 PM
Ignite Modification Date:
2026-02-22 @ 4:52 PM
Study NCT ID:
NCT04029350
Status:
UNKNOWN
Last Update Posted:
2019-08-21
First Post:
2019-07-21
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Study of Anlotinib Combined With Osimertinib as Second-line Treatment in Stage IIIb-IV NSCLC With Confirmed EGFRm and T790M
Sponsor:
Tianjin Medical University Cancer Institute and Hospital
Organization: